Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 2
1987 13
1988 7
1989 9
1990 8
1991 7
1992 6
1993 10
1994 15
1995 5
1996 2
1997 4
1998 4
1999 2
2000 2
2001 5
2002 7
2003 10
2004 3
2005 4
2006 1
2007 2
2008 3
2009 2
2010 1
2011 1
2012 1
2013 1
2015 1
2019 2
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of rebamipide/nizatidine in patients with erosive gastritis: A randomized, multicenter, phase 4 study.
Kang D, Choi MG, Shim KN, Jung HK, Nam SJ, Park JH, Kim SG, Kim NH, Hong SJ, Jeon TJ, Chung JI, Lee HL, Lee JY, Kim TO, Lee CM, Kim SM, Kim JH, Kim JE, Moon JS, Kim HD, Lee WS, Park HJ. Kang D, et al. World J Gastroenterol. 2024 Dec 28;30(48):5152-5161. doi: 10.3748/wjg.v30.i48.5152. World J Gastroenterol. 2024. PMID: 39735267 Free PMC article. Clinical Trial.
BACKGROUND: For the treatment of gastritis, rebamipide, a mucoprotective agent, and nizatidine, a gastric acid suppressant, are commonly employed individually. AIM: To compare the efficacy of Mucotra( ) SR (rebamipide 150 mg) and Axid( ) (nizatidine 150 mg) combinat …
BACKGROUND: For the treatment of gastritis, rebamipide, a mucoprotective agent, and nizatidine, a gastric acid suppressant, are commo …
Safety of nizatidine in clinical trials conducted in the USA and Europe.
Cloud ML. Cloud ML. Scand J Gastroenterol Suppl. 1987;136:29-36. doi: 10.3109/00365528709094483. Scand J Gastroenterol Suppl. 1987. PMID: 2892253 Clinical Trial.
The safety of nizatidine as treatment for active duodenal or gastric ulcer disease or as maintenance therapy following ulcer healing was assessed in 3800 nizatidine-treated individuals in clinical trials conducted in the USA and Europe. ...Minimal changes in uric ac …
The safety of nizatidine as treatment for active duodenal or gastric ulcer disease or as maintenance therapy following ulcer healing …
Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying.
Futagami S, Shimpuku M, Song JM, Kodaka Y, Yamawaki H, Nagoya H, Shindo T, Kawagoe T, Horie A, Gudis K, Iwakiri K, Sakamoto C. Futagami S, et al. Digestion. 2012;86(2):114-21. doi: 10.1159/000339111. Epub 2012 Jul 27. Digestion. 2012. PMID: 22846371 Clinical Trial.
In addition, nizatidine treatment also significantly improved gastroesophageal symptoms (16/30; 53%) compared to those treated with placebo (0/30; 0%). ...There were no significant differences in ghrelin levels between nizatidine treatment and placebo therapy. CONCL …
In addition, nizatidine treatment also significantly improved gastroesophageal symptoms (16/30; 53%) compared to those treated with p …
Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulcer. Nizatidine Multicenter Duodenal Ulcer Study Group.
Cherner JA, Cloud ML, Offen WW, Latz JE. Cherner JA, et al. Am J Gastroenterol. 1989 Jul;84(7):769-74. Am J Gastroenterol. 1989. PMID: 2568086 Clinical Trial.
Nizatidine, a new H2-receptor antagonist for the treatment of duodenal ulcer disease, was compared with cimetidine in an 8-wk, randomized, double-blind, multicenter clinical trial. Patients were randomly allocated to receive either nizatidine 300 mg h.s. or cimetidi …
Nizatidine, a new H2-receptor antagonist for the treatment of duodenal ulcer disease, was compared with cimetidine in an 8-wk, random …
Histamine H2-receptor antagonists.
Pounder R. Pounder R. Baillieres Clin Gastroenterol. 1988 Jul;2(3):593-608. doi: 10.1016/s0950-3528(88)80007-1. Baillieres Clin Gastroenterol. 1988. PMID: 2901868 Review.
Developmental pharmacokinetics and pharmacodynamics of nizatidine.
Abdel-Rahman SM, Johnson FK, Connor JD, Staiano A, Dupont C, Tolia V, Winter H, Gauthier-Dubois G, Kearns GL. Abdel-Rahman SM, et al. J Pediatr Gastroenterol Nutr. 2004 Apr;38(4):442-51. doi: 10.1097/00005176-200404000-00015. J Pediatr Gastroenterol Nutr. 2004. PMID: 15085026 Clinical Trial.
Nizatidine and N-desmethylnizatidine concentrations were measured in serial post-dose plasma samples by a high-performance liquid chromatographic assay with mass spectrometric detection. ...The age-associated changes in lambda z observed for nizatidine and its metab …
Nizatidine and N-desmethylnizatidine concentrations were measured in serial post-dose plasma samples by a high-performance liquid chr …
Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
Orenstein SR, Gremse DA, Pantaleon CD, Kling DF, Rotenberg KS. Orenstein SR, et al. Clin Ther. 2005 Apr;27(4):472-83. doi: 10.1016/j.clinthera.2005.04.008. Clin Ther. 2005. PMID: 15922820 Clinical Trial.
The original study design specified that patients aged 5 days through 12 years at study start be given a nizatidine capsule dissolved in infant formula or apple juice depending on patient age ("extemporaneous solution"). ...Subsequently, an additional 44 children aged < …
The original study design specified that patients aged 5 days through 12 years at study start be given a nizatidine capsule dissolved …
Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia.
Hansen JM, Bytzer P, Schaffalitzky de Muckadell OB. Hansen JM, et al. Am J Gastroenterol. 1998 Mar;93(3):368-74. doi: 10.1111/j.1572-0241.1998.00368.x. Am J Gastroenterol. 1998. PMID: 9517642 Clinical Trial.
A total of 330 patients with either minor or no abnormalities at endoscopy were randomized to double blind treatment with cisapride 10 mg t.i.d., nizatidine 300 mg at night, or placebo for 2 wk. RESULTS: A symptomatic response was found in 62% of patients on cisapride (the …
A total of 330 patients with either minor or no abnormalities at endoscopy were randomized to double blind treatment with cisapride 10 mg t. …
Twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg.
Savarino V, Mela GS, Zentilin P, Cutela P, Mele R, Celle G. Savarino V, et al. J Clin Pharmacol. 1993 Jan;33(1):70-4. doi: 10.1002/j.1552-4604.1993.tb03906.x. J Clin Pharmacol. 1993. PMID: 8429117 Clinical Trial.
This study was carried out to assess the effects on gastric acidity of placebo twice daily (bid), nizatidine 150 mg bid, nizatidine 300 mg bid, and ranitidine 300 mg bid by means of continuous 24-hour intragastric pH monitoring. ...Three hundred milligrams twice dai …
This study was carried out to assess the effects on gastric acidity of placebo twice daily (bid), nizatidine 150 mg bid, nizatidin …
Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients.
Futagami S, Yamawaki H, Izumi N, Shimpuku M, Kodaka Y, Wakabayashi T, Nagoya H, Shindo T, Kawagoe T, Gudis K, Itoh T, Sakamoto C. Futagami S, et al. J Gastroenterol Hepatol. 2013 Aug;28(8):1314-20. doi: 10.1111/jgh.12236. J Gastroenterol Hepatol. 2013. PMID: 23611167 Clinical Trial.
The aim of this study is to evaluate the risk factors associated with sleep disorders and the clinical response to nizatidine therapy for sleep disorders in Rome III-based FD patients. METHODS: We enrolled 94 FD patients and 52 healthy volunteers. ...Thirty-four FD patient …
The aim of this study is to evaluate the risk factors associated with sleep disorders and the clinical response to nizatidine therapy …
140 results